Type 2 diabetes mellitus
Conditions
Interventions
The patients are treated with dulaglutide instead of exenatide extended-release from the start to the 26th week.On the 26th week the patients choose a drug from exenatide extended-release and dulaglut
Sponsors
Haga Diabetes Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Type 2 diabetic patients treated with exenatide extended-release HbA1c is higher than or equal to 6.0% Patients are not planned to be treated with prohibited combined drugs
Exclusion criteria
Exclusion criteria: Type 1 diabetic patients. Patients with a history of severe ketosis or diabetic coma in previous 6 months. Patients with severe infection, before/after surgery or severe traumatic injury. Patients to have a plan to be pregnant. Patients with severe gastroenteric disturbance as exemplified by severe gastro-paresis. Patients with a history of pancreatitis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of HbA1c,body weight at the 26th and the 52th week. Ratio of dulaglutide/exenatide-extended-release which patients choose. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of data shown below at the 26th and the 52th week. AST, ALT, gamma-GTP, LDL-C, HDL-C,TG, non-HOL-C, serum creatinine, serum UA, eGFR, 1,5-AG, self-monitoring blood glucose, Urine albumin(mg/gCr),Urine protein (g/gCr) | — |
Countries
Japan
Contacts
Public ContactTatsuya Haga
Haga Diabetes Clinic internal medicine
Outcome results
None listed